sotalol has been researched along with Ventricular Fibrillation in 122 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sotalol and verapamil alone reduce reentry incidence during ventricular fibrillation (VF)." | 7.88 | Effects of combination of sotalol and verapamil on initiation, maintenance, and termination of ventricular fibrillation in swine hearts. ( Dosdall, DJ; Huang, J; Ideker, RE; Jin, Q; Li, L; Rogers, JM; Wu, L, 2018) |
| "Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present." | 7.81 | Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. ( Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015) |
| "The characteristics of reentrant circuits during short duration ventricular fibrillation (SDVF; 20 s in duration) and the role of Ca(++) and rapid-activating delayed rectifier potassium currents during long duration ventricular fibrillation (LDVF; up to 10 min in duration) were investigated using verapamil and sotalol." | 7.80 | Verapamil reduces incidence of reentry during ventricular fibrillation in pigs. ( Dosdall, DJ; Huang, J; Ideker, RE; Jin, Q; Li, L; Rogers, JM, 2014) |
| "The effects of d,l-sotalol at therapeutic concentrations ( | 7.75 | d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. ( Horng, TL; Hsieh, YC; Lin, SF; Lin, TC; Ting, CT; Wu, TJ, 2009) |
| "We tested the hypothesis that procainamide and sotalol combined have greater beneficial effects on restitution, on the dispersion of refractoriness, and on decreasing the complexity of ventricular fibrillation (VF) than either drug alone." | 7.74 | Effects of procainamide and sotalol on restitution properties, dispersion of refractoriness, and ventricular fibrillation activation patterns in pigs. ( Chen, X; Huang, J; Ideker, RE; Jin, Q; Smith, WM, 2008) |
| "We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms." | 7.72 | Effectiveness of sotalol treatment in symptomatic Brugada syndrome. ( Chen, S; Chiamvimonvat, N; Glatter, KA; Keating, M; Scheinman, MM; Wang, Q, 2004) |
| " Under control conditions and after flecainide, verapamil, or d,l-sotalol, the dominant frequency (FrD), type of activation maps, conduction velocity, functional refractory period, and wavelength (WL) of excitation were determined during ventricular fibrillation (VF)." | 7.70 | Alteration of ventricular fibrillation by flecainide, verapamil, and sotalol: an experimental study. ( Cánoves, J; Chorro, FJ; Guerrero, J; López-Merino, V; Mainar, L; Sanchis, J; Such, L, 2000) |
| " We present a case of massive imipramine overdose complicated by ventricular fibrillation and a prolonged period of cardiovascular collapse." | 7.69 | Tricyclic poisoning--successful management of ventricular fibrillation following massive overdose of imipramine. ( Alahakoon, TI; Bentley, SC; Sandeman, DJ, 1997) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| " This study was performed to assess the effect of sotalol on the dispersion of refractoriness in experimental myocardial infarction." | 7.69 | Dispersion of ventricular refractoriness in experimental myocardial infarction: effect of sotalol. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hindricks, G; Lubiński, A; Shenasa, M; Vogt, B, 1994) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 7.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 7.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studies to establish the therapeutic efficacy of sotalol." | 7.67 | Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. ( Brachmann, J; Cobbe, S; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1984) |
| "Programmed ventricular stimulation and ambulatory electrocardiography were performed both before and during oral sotalol therapy in 39 patients with ventricular tachyarrhythmia inducible by programmed stimulation (sustained ventricular tachycardia [n = 31], ventricular fibrillation [n = 3], nonsustained ventricular tachycardia [n = 5])." | 7.67 | Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. ( Bach, P; Haberl, R; Steinbeck, G, 1986) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 7.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "The effect of (+/-)-sotalol (a beta-blocker with class III antiarrhythmic activity) against reperfusion-induced arrhythmias was studied in artificially ventilated, open-chest, Sprague-Dawley and Wistar rats." | 7.67 | Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats. ( De Champlain, J; Lamontagne, D; Nadeau, R; Rochette, L; Vermeulen, M; Yamaguchi, N, 1989) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 7.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 7.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| "Sotalol has an important indication for the management of ventricular tachyarrhythmias." | 6.38 | Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. ( Campbell, RW; Furniss, SS, 1993) |
| "Oral sotalol 171 +/- 58 mg was administered before and after device implantation in 25 patients receiving implanted defibrillators." | 5.29 | Effect of sotalol on ventricular fibrillation and defibrillation in humans. ( Dorian, P; Newman, D, 1993) |
| "Sotalol is a unique beta-blocker that lengthens cardiac repolarization and effective refractory period (ERP)." | 5.27 | Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Feld, G; Hendrickson, J; Nademanee, K; Singh, BN; Singh, PN, 1985) |
| "A distinct phase of ventricular arrhythmias was evident about 10 to 30 min after ligation." | 5.27 | Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP. ( Gihwala, D; Hamm, CW; Muller, CA; Opie, LH; Peisach, M, 1986) |
| "Sotalol is not superior to lignocaine for treatment of ventricular fibrillation refractory to multiple shocks." | 5.11 | Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. ( Adelstein, BA; Hall, J; Ho, D; Kovoor, P; Kruit, R; Love, A; Ross, DL; Sadick, N, 2005) |
| "To evaluate the clinical efficacy of d-sotalol, 84 patients with a history of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), who had inducible sustained VT/VT at baseline electrophysiologic study (EPS), were investigated after intravenous (IV) d-sotalol (1." | 5.07 | Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias. ( Beyer, T; Brachmann, J; Enders, B; Kübler, W; Montero, M; Schöls, W, 1993) |
| "Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present." | 3.81 | Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. ( Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015) |
| "The characteristics of reentrant circuits during short duration ventricular fibrillation (SDVF; 20 s in duration) and the role of Ca(++) and rapid-activating delayed rectifier potassium currents during long duration ventricular fibrillation (LDVF; up to 10 min in duration) were investigated using verapamil and sotalol." | 3.80 | Verapamil reduces incidence of reentry during ventricular fibrillation in pigs. ( Dosdall, DJ; Huang, J; Ideker, RE; Jin, Q; Li, L; Rogers, JM, 2014) |
| "The effects of d,l-sotalol at therapeutic concentrations ( | 3.75 | d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. ( Horng, TL; Hsieh, YC; Lin, SF; Lin, TC; Ting, CT; Wu, TJ, 2009) |
| "We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms." | 3.72 | Effectiveness of sotalol treatment in symptomatic Brugada syndrome. ( Chen, S; Chiamvimonvat, N; Glatter, KA; Keating, M; Scheinman, MM; Wang, Q, 2004) |
| " A total of 152 patients with remote myocardial infarction and documented ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent coronary angiography and programmed ventricular stimulation before and after oral administration of d,l-sotalol (240-640 mg/day)." | 3.70 | Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hoppe, UC, 2000) |
| "Implantable cardioverter-defibrillators (ICDs) and d,l-sotalol are widely used to treat ventricular tachyarrhythmia and ventricular fibrillation (VT/VF)." | 3.69 | Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Hammel, D; Haverkamp, W, 1996) |
| " This study was performed to assess the effect of sotalol on the dispersion of refractoriness in experimental myocardial infarction." | 3.69 | Dispersion of ventricular refractoriness in experimental myocardial infarction: effect of sotalol. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hindricks, G; Lubiński, A; Shenasa, M; Vogt, B, 1994) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 3.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "The aim of this study was to assess the antiarrhythmic efficacy and safety of d,l-sotalol in patients with ventricular tachycardia (VT) or ventricular fibrillation (VF) and in survivors of cardiac arrest and to identify the factors that are associated with arrhythmia suppression and therefore might be helpful in predicting drug efficacy." | 3.69 | Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hief, C; Lammers, A; Martinez-Rubio, A; Mühlenkamp, S; Wichter, T, 1997) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "Ventricular fibrillation induced in animals pretreated with sotalol, a class III antiarrhythmic agent, would spontaneously terminate and revert into a sinus rhythm." | 3.69 | Is cyclic AMP involved in the defibrillating effect of sotalol? ( Manoach, M; Miyachi, E; Uchiyama, H; Watanabe, Y, 1995) |
| " We present a case of massive imipramine overdose complicated by ventricular fibrillation and a prolonged period of cardiovascular collapse." | 3.69 | Tricyclic poisoning--successful management of ventricular fibrillation following massive overdose of imipramine. ( Alahakoon, TI; Bentley, SC; Sandeman, DJ, 1997) |
| "d-Sotalol is not effective against myocardial ischemia-dependent ventricular fibrillation in the presence of elevated sympathetic activity." | 3.69 | Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. ( Diehl, L; Hirao, K; Lazzara, R; Nakagawa, H; Napolitano, C; Priori, SG; Schwartz, PJ; Vanoli, E, 1995) |
| " The time to onset of the first arrhythmia and ventricular fibrillation, induced by intravenous infusion of ouabain, was shortened in the presence of AM 92016." | 3.69 | The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016. ( Hagerty, MJ; Kane, KA; Wainwright, CL, 1996) |
| "The aim of this study was to compare the effects of d- and dl-sotalol on the ventricular fibrillation threshold (VFT) and the effective refractory period (VERP) in anaesthetized cats subjected to coronary artery occlusion." | 3.68 | Comparative antifibrillatory effects of d- and dl-sotalol in normal and ischaemic ventricular muscle of the cat. ( Gwilt, M; Kane, KA; Kwan, YW; Solca, AM; Wadsworth, RM, 1990) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 3.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| " and the ventricular fibrillation threshold at doses between 3-100 micrograms/kg and was 80-1000 times more potent than sematilide, racemic sotalol, d-sotalol or quinidine." | 3.68 | Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs. ( Blackburn, KJ; Burges, RA; Gwilt, M; Higgins, AJ; Milne, AA; Solca, AM, 1992) |
| "The effect of (+/-)-sotalol (a beta-blocker with class III antiarrhythmic activity) against reperfusion-induced arrhythmias was studied in artificially ventilated, open-chest, Sprague-Dawley and Wistar rats." | 3.67 | Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats. ( De Champlain, J; Lamontagne, D; Nadeau, R; Rochette, L; Vermeulen, M; Yamaguchi, N, 1989) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 3.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 3.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "5 V, 750 ms) or programmed ventricular stimulation, creation of a small myocardial infarction, and application of antiarrhythmic drugs (ajmalin, lidocaine, sotalol)." | 3.67 | Acute induction of sustained ventricular tachycardia: a new porcine model. ( Lüderitz, B; Nitsch, J; Schmid, C, 1989) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 3.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| "Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studies to establish the therapeutic efficacy of sotalol." | 3.67 | Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. ( Brachmann, J; Cobbe, S; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1984) |
| "Programmed ventricular stimulation and ambulatory electrocardiography were performed both before and during oral sotalol therapy in 39 patients with ventricular tachyarrhythmia inducible by programmed stimulation (sustained ventricular tachycardia [n = 31], ventricular fibrillation [n = 3], nonsustained ventricular tachycardia [n = 5])." | 3.67 | Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. ( Bach, P; Haberl, R; Steinbeck, G, 1986) |
| "Eighteen patients with sustained ventricular tachycardia underwent serial electrophysiological studies to establish the therapeutic efficacy of sotalol as compared to other available anti-arrhythmic agents." | 3.67 | Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol. ( Brachmann, J; Cobbe, SM; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1985) |
| "D,l-sotalol is an important antiarrhythmic agent to prevent recurrences of sustained ventricular tachyarrhythmias (VT/VF)." | 2.69 | Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. ( Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999) |
| "Patients with ventricular tachycardia also had either syncope or other serious cardiac symptoms, along with a left ventricular ejection fraction of 0." | 2.68 | A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. ( , 1997) |
| "In this trial, rates of recurrence of arrhythmias were higher (37% at one year and 66% at four years) than generally reported, but cardiac and arrhythmia mortality were comparable or lower than generally reported." | 2.67 | Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial. ( Lazzara, R, 1994) |
| "486 patients with documented ventricular tachycardia or resuscitated sudden death were randomized to EPS (n = 242) or HM (n = 244) and underwent serial drug testing with up to six antiarrhythmics; in the EPS limb a drug efficacy prediction was achieved in 108 patients (45%), compared to 188 (77%) in the HM limb (P < 0." | 2.67 | Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial. ( Klein, RC, 1993) |
| "Patients with symptomatic ventricular tachycardia, ventricular fibrillation, or aborted sudden cardiac death remain at high risk for arrhythmia recurrence." | 2.40 | Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. ( Borggrefe, M; Breithardt, G; Eckardt, L; Haverkamp, W, 1997) |
| "Sotalol was 1 of 2 drugs selected for comparison with implantable defibrillators in the recent National Institutes of Health Antiarrhythmics versus Implantable Defibrillator (AVID) study." | 2.40 | Sotalol: An important new antiarrhythmic. ( Anderson, JL; Prystowsky, EN, 1999) |
| "Sotalol is a unique compound with several potential antiarrhythmic mechanisms, including beta blockade (class II activity), action potential duration prolongation (class III activity), and possibly reduction of QT dispersion." | 2.39 | Evolving role of sotalol in the management of ventricular tachyarrhythmias. ( McGovern, BA; O'Callaghan, PA, 1996) |
| "Pharmacological therapy of cardiac arrhythmias continues to evolve, with an increasing shift from class I to class III compounds and beta-blockers." | 2.39 | Class III antiarrhythmic drugs. ( Ahmed, R; Singh, BN, 1994) |
| "sustained ventricular tachycardia, ventricular fibrillation, aborted sudden cardiac death) are changing." | 2.39 | [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Haverkamp, W, 1996) |
| "Sotalol has an important indication for the management of ventricular tachyarrhythmias." | 2.38 | Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. ( Campbell, RW; Furniss, SS, 1993) |
| "Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms." | 2.38 | Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias. ( Anderson, JL, 1990) |
| "Antazoline is a first-generation antihistamine with antiarrhythmic properties." | 1.48 | Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. ( Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Sterneberg, M, 2018) |
| "Duration of ventricular tachycardia (VT) episodes was reduced from 15." | 1.37 | First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. ( Bhandari, A; Dow, JS; Kloner, RA, 2011) |
| "Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard ratio [HR]: 2." | 1.35 | Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. ( Cannom, DS; Estes, NA; Glidden, DV; Marcus, F; Marcus, GM; Polonsky, B; Scheinman, MM; Smith, LM; Zareba, W, 2009) |
| " Such an accelerated dosing regimen neither shortened hospitalization nor had any effect on treatment efficacy in this retrospective analysis." | 1.33 | Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias. ( Gerling, BR; Greenberg, ML; Holzberger, PT; Jones, DR; Juriansz, GJ; Kim, RJ, 2006) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | 1.31 | [Ion channels and arrhythmias]. ( Borchard, U; Hafner, D, 2000) |
| "Thirty patients with VT/VF (age: 57+/-11 years, 20 patients with coronary heart disease, 7 patients with no structural heart disease, 3 with others) and reproducible induction of VT/VF (28 patients VT, two patients VF) in a baseline PVS, were suppressible with sotalol (mean dosage 395+/-137 mg) in a subsequent PVS." | 1.30 | Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. ( Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999) |
| "Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the arrhythmia during programmed stimulation." | 1.30 | Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. ( Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1997) |
| "d-Sotalol did not suppress the reperfusion VF in halothane anesthetized animals, nor did it show proarrhythmic effects." | 1.29 | Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. ( Awaji, T; Haruno, A; Hashimoto, K; Hirasawa, A; Wu, Z; Xue, Y, 1995) |
| "Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods." | 1.29 | From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. ( Lazzara, R, 1996) |
| " But further programmed ventricular stimulation was uneventful after the sotalol dosage had been increased to 160 mg three times daily." | 1.29 | [Reproducible ventricular flutter during programming of a DDD pacemaker]. ( Bienstein, B; Grosse-Heitmeyer, W; Liebetrau, M; Stauff, L, 1993) |
| "Sotalol is a class III antiarrhythmic drug with additional beta-blocker activity that has been shown to be effective in supraventricular and ventricular arrhythmias." | 1.29 | Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. ( Boone, J; Kerr, CR; Mohama, R; Yeung-Lai-Wah, JA; Young, GD, 1994) |
| "Undersensing of ventricular tachyarrhythmias is a potentially serious problem, as it may lead to failure to deliver therapy." | 1.29 | Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming. ( Damle, RS; Kelly, PA; Mann, DE; Reiter, MJ, 1994) |
| " Compound 5 was shown to have good oral bioavailability and a favorable hemodynamic profile to produce a 3-fold increase of the ventricular fibrillation threshold and to terminate ventricular fibrillation, restoring sinus rhythm in anesthetized dogs." | 1.28 | Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides. ( Bagli, JF; Ellingboe, JW; Kitzen, JM; Moubarak, IF; Nguyen, TT; Parsons, RW; Spinelli, W; Von Engen, D; Winkley, MW, 1992) |
| "Sotalol was found to be effective therapy for a subset of patients with ventricular tachycardia unresponsive to type IA drugs." | 1.27 | Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. ( Gonzalez, R; Griffin, JC; Herre, JM; Sauve, MJ; Scheinman, MM; Sharkey, H, 1988) |
| "Correspondingly, ventricular arrhythmias and fibrillation were almost completely prevented by metoprolol, d-sotalol or verapamil, but increased by lidocaine." | 1.27 | Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion. ( Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| "Sotalol is a unique beta-blocker that lengthens cardiac repolarization and effective refractory period (ERP)." | 1.27 | Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Feld, G; Hendrickson, J; Nademanee, K; Singh, BN; Singh, PN, 1985) |
| "A distinct phase of ventricular arrhythmias was evident about 10 to 30 min after ligation." | 1.27 | Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP. ( Gihwala, D; Hamm, CW; Muller, CA; Opie, LH; Peisach, M, 1986) |
| "Quinidine combined with propranolol produces antiarrhythmic synergism." | 1.26 | Comparative antiarrhythmic activity of quinidine combined with propranolol and with sotalol. ( Lawson, JW; Wojciechowski, NJ, 1981) |
| "Occlusion of the LAD artery produced arrhythmia in all of the animals, with 39% developing ventricular fibrillation (VF)." | 1.25 | Influence of the adrenal medulla on cardiac rhythm disturbances following acute coronary artery occlusions. ( Kelliher, GJ; Roberts, J; Widmer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (21.31) | 18.7374 |
| 1990's | 61 (50.00) | 18.2507 |
| 2000's | 26 (21.31) | 29.6817 |
| 2010's | 8 (6.56) | 24.3611 |
| 2020's | 1 (0.82) | 2.80 |
| Authors | Studies |
|---|---|
| Ellingboe, JW | 1 |
| Spinelli, W | 2 |
| Winkley, MW | 1 |
| Nguyen, TT | 1 |
| Parsons, RW | 2 |
| Moubarak, IF | 1 |
| Kitzen, JM | 1 |
| Von Engen, D | 1 |
| Bagli, JF | 1 |
| Shiohira, S | 1 |
| Kawabata, M | 1 |
| Goya, M | 1 |
| Maeda, S | 1 |
| Sasano, T | 1 |
| Hirao, K | 2 |
| Ellermann, C | 1 |
| Sterneberg, M | 1 |
| Kochhäuser, S | 1 |
| Dechering, DG | 1 |
| Fehr, M | 1 |
| Eckardt, L | 5 |
| Frommeyer, G | 2 |
| Jin, Q | 3 |
| Wu, L | 1 |
| Dosdall, DJ | 2 |
| Li, L | 2 |
| Rogers, JM | 2 |
| Ideker, RE | 3 |
| Huang, J | 3 |
| Agusala, K | 1 |
| Oesterle, A | 1 |
| Kulkarni, C | 1 |
| Caprio, T | 1 |
| Subacius, H | 1 |
| Passman, R | 1 |
| Tang, L | 1 |
| Maeda, K | 1 |
| Takagi, M | 1 |
| Tatsumi, H | 1 |
| Nakagawa, E | 1 |
| Yoshiyama, M | 1 |
| Hsieh, YC | 1 |
| Horng, TL | 1 |
| Lin, SF | 1 |
| Lin, TC | 1 |
| Ting, CT | 1 |
| Wu, TJ | 1 |
| Srivastava, A | 1 |
| Khan, MA | 1 |
| Watkiss, J | 1 |
| Marcus, GM | 1 |
| Glidden, DV | 1 |
| Polonsky, B | 1 |
| Zareba, W | 1 |
| Smith, LM | 1 |
| Cannom, DS | 1 |
| Estes, NA | 1 |
| Marcus, F | 1 |
| Scheinman, MM | 3 |
| Mitchell, LB | 1 |
| Venkataraman, G | 1 |
| Strickberger, SA | 1 |
| Dizon, J | 1 |
| Chen, K | 1 |
| Dizon, S | 1 |
| Biviano, A | 1 |
| Whang, W | 1 |
| Ehlert, F | 1 |
| Vazquez, J | 1 |
| Nazif, T | 1 |
| Garan, H | 2 |
| Kloner, RA | 1 |
| Dow, JS | 1 |
| Bhandari, A | 1 |
| Rajamani, S | 1 |
| Grundmann, F | 1 |
| Stypmann, J | 1 |
| Osada, N | 1 |
| Breithardt, G | 10 |
| Belardinelli, L | 1 |
| Milberg, P | 2 |
| Spivack, C | 1 |
| Kirchhof, P | 1 |
| Haverkamp, W | 10 |
| Sims, JJ | 1 |
| Miller, AW | 1 |
| Ujhelyi, MR | 1 |
| Glatter, KA | 1 |
| Wang, Q | 1 |
| Keating, M | 1 |
| Chen, S | 1 |
| Chiamvimonvat, N | 1 |
| Kovoor, P | 1 |
| Love, A | 1 |
| Hall, J | 1 |
| Kruit, R | 1 |
| Sadick, N | 1 |
| Ho, D | 1 |
| Adelstein, BA | 1 |
| Ross, DL | 1 |
| Kowey, PR | 1 |
| Yan, GX | 1 |
| Shukla, G | 1 |
| Chaudhry, GM | 1 |
| Orlov, M | 1 |
| Hoffmeister, P | 1 |
| Haffajee, C | 1 |
| Connolly, SJ | 2 |
| Dorian, P | 5 |
| Roberts, RS | 1 |
| Gent, M | 2 |
| Bailin, S | 1 |
| Fain, ES | 1 |
| Thorpe, K | 1 |
| Champagne, J | 2 |
| Talajic, M | 1 |
| Coutu, B | 1 |
| Gronefeld, GC | 1 |
| Hohnloser, SH | 2 |
| Iavelov, IS | 1 |
| Roberts, R | 1 |
| Israel, CW | 1 |
| Fain, E | 1 |
| Kim, RJ | 1 |
| Juriansz, GJ | 1 |
| Jones, DR | 1 |
| Gerling, BR | 1 |
| Holzberger, PT | 1 |
| Greenberg, ML | 1 |
| Chen, X | 1 |
| Smith, WM | 1 |
| Patterson, E | 2 |
| Lynch, JJ | 2 |
| Lucchesi, BR | 3 |
| Lawson, JW | 2 |
| Wojciechowski, NJ | 1 |
| Laakso, M | 2 |
| Pentikäinen, PJ | 2 |
| Pyörälä, K | 1 |
| Neuvonen, PJ | 1 |
| Senges, J | 2 |
| Lengfelder, W | 2 |
| Jauernig, R | 2 |
| Czygan, E | 2 |
| Brachmann, J | 3 |
| Rizos, I | 2 |
| Cobbe, S | 1 |
| Kübler, W | 3 |
| Lampainen, E | 1 |
| Hashimoto, K | 1 |
| Haruno, A | 1 |
| Hirasawa, A | 1 |
| Awaji, T | 1 |
| Xue, Y | 1 |
| Wu, Z | 1 |
| Singer, I | 1 |
| Lazzara, R | 3 |
| Lu, HR | 1 |
| Remeysen, P | 1 |
| De Clerck, F | 1 |
| Usui, M | 1 |
| Inoue, H | 1 |
| Saihara, S | 1 |
| Sugimoto, T | 1 |
| Vanoli, E | 2 |
| Priori, SG | 1 |
| Nakagawa, H | 1 |
| Napolitano, C | 1 |
| Diehl, L | 1 |
| Schwartz, PJ | 3 |
| Lubiński, A | 1 |
| Hindricks, G | 3 |
| Shenasa, M | 2 |
| Vogt, B | 1 |
| Borggrefe, M | 8 |
| Hallstrom, AP | 1 |
| Greene, HL | 2 |
| Wyse, DG | 1 |
| Zipes, D | 1 |
| Epstein, AE | 1 |
| Domanski, MJ | 1 |
| Schron, EB | 1 |
| Aliot, E | 1 |
| Sadoul, N | 1 |
| De Chillou, C | 1 |
| Mann, DE | 1 |
| Kelly, PA | 1 |
| Damle, RS | 1 |
| Reiter, MJ | 1 |
| Raza, A | 1 |
| Young, GD | 1 |
| Kerr, CR | 1 |
| Mohama, R | 1 |
| Boone, J | 1 |
| Yeung-Lai-Wah, JA | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Van de Loo, A | 1 |
| Hohnloser, S | 1 |
| Just, H | 1 |
| Singh, BN | 3 |
| Ahmed, R | 1 |
| Bienstein, B | 1 |
| Grosse-Heitmeyer, W | 1 |
| Liebetrau, M | 1 |
| Stauff, L | 1 |
| Klein, RC | 1 |
| Schöls, W | 1 |
| Beyer, T | 1 |
| Montero, M | 1 |
| Enders, B | 1 |
| Newman, D | 1 |
| Campbell, RW | 1 |
| Furniss, SS | 1 |
| Uchiyama, H | 2 |
| Manoach, M | 4 |
| Miyachi, E | 2 |
| Watanabe, Y | 2 |
| Brooks, MM | 1 |
| Hallstrom, A | 1 |
| Peckova, M | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 2 |
| Manning, AS | 1 |
| Bruyninckx, C | 1 |
| Ramboux, J | 1 |
| Hull, SS | 1 |
| Adamson, PB | 1 |
| Foreman, RD | 1 |
| Shimizu, W | 1 |
| Kurita, T | 1 |
| Suyama, K | 1 |
| Aihara, N | 1 |
| Kamakura, S | 1 |
| Shimomura, K | 1 |
| Böcker, D | 2 |
| Block, M | 2 |
| Hammel, D | 1 |
| Kirchhof, PF | 1 |
| Fabritz, CL | 1 |
| Zabel, M | 1 |
| Franz, MR | 1 |
| O'Callaghan, PA | 1 |
| McGovern, BA | 2 |
| Hagerty, MJ | 1 |
| Wainwright, CL | 1 |
| Kane, KA | 2 |
| Kühlkamp, V | 3 |
| Mermi, J | 3 |
| Mewis, C | 3 |
| Seipel, L | 3 |
| Neuzner, J | 1 |
| Bahawar, H | 1 |
| Berkowitsch, A | 1 |
| Michel, U | 1 |
| Schlepper, M | 1 |
| Pitschner, HF | 1 |
| Martinez-Rubio, A | 1 |
| Hief, C | 1 |
| Lammers, A | 1 |
| Mühlenkamp, S | 1 |
| Wichter, T | 1 |
| Sandeman, DJ | 1 |
| Alahakoon, TI | 1 |
| Bentley, SC | 1 |
| Göttker, U | 1 |
| Madeja, M | 1 |
| Johna, R | 1 |
| Bosch, RF | 2 |
| Anderson, JL | 2 |
| Prystowsky, EN | 1 |
| Reiffel, JA | 1 |
| Naccarella, F | 1 |
| Rolli, A | 1 |
| Carboni, A | 1 |
| Finardi, A | 1 |
| Aurier, E | 1 |
| Favaro, L | 1 |
| Contini, S | 1 |
| Gherli, T | 1 |
| Caponi, D | 1 |
| Maranga, SS | 1 |
| Lepera, G | 1 |
| Bartoletti, A | 1 |
| Capucci, A | 1 |
| Aschieri, D | 1 |
| Villani, GQ | 1 |
| Varon, D | 1 |
| Tribulova, N | 2 |
| Shainberg, A | 1 |
| Zinman, T | 1 |
| Isaack, A | 1 |
| Imanaga, I | 1 |
| Chorro, FJ | 1 |
| Cánoves, J | 1 |
| Guerrero, J | 1 |
| Mainar, L | 1 |
| Sanchis, J | 1 |
| Such, L | 1 |
| López-Merino, V | 1 |
| Borchard, U | 1 |
| Hafner, D | 1 |
| Hoppe, UC | 1 |
| Brooks, RR | 1 |
| Finch, SL | 1 |
| Cooley, R | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Konecná, P | 1 |
| Dvorák, R | 1 |
| Semrád, B | 1 |
| Kovács, A | 1 |
| Gyönös, I | 1 |
| Magyar, J | 1 |
| Bányász, T | 1 |
| Nánási, PP | 1 |
| Spedding, M | 1 |
| Szénási, G | 1 |
| Qi, X | 1 |
| Boriani, G | 1 |
| Biffi, M | 1 |
| Bacchi, L | 1 |
| Martignani, C | 1 |
| Zannoli, R | 1 |
| Butrous, GS | 1 |
| Branzi, A | 1 |
| Kelliher, GJ | 1 |
| Widmer, C | 1 |
| Roberts, J | 1 |
| Huikuri, HV | 1 |
| Yli-Mäyry, S | 1 |
| Colatsky, TJ | 1 |
| Gwilt, M | 2 |
| Blackburn, KJ | 1 |
| Burges, RA | 1 |
| Higgins, AJ | 1 |
| Milne, AA | 1 |
| Solca, AM | 2 |
| Kwan, YW | 1 |
| Wadsworth, RM | 1 |
| Brown, DC | 1 |
| Godman, MJ | 1 |
| Trappe, HJ | 2 |
| Klein, H | 2 |
| Lichtlen, P | 1 |
| Nademanee, K | 2 |
| Wang, M | 1 |
| Lamontagne, D | 1 |
| Rochette, L | 1 |
| Vermeulen, M | 1 |
| Yamaguchi, N | 1 |
| Nadeau, R | 1 |
| De Champlain, J | 1 |
| Jordaens, LJ | 1 |
| Palmer, A | 1 |
| Clement, DL | 1 |
| Kuchar, DL | 1 |
| Venditti, FJ | 1 |
| Finkelstein, D | 1 |
| Rottman, JN | 1 |
| McComb, J | 1 |
| Ruskin, JN | 1 |
| Schmid, C | 1 |
| Nitsch, J | 1 |
| Lüderitz, B | 1 |
| Muller, CA | 1 |
| Opie, LH | 1 |
| Hamm, CW | 1 |
| Peisach, M | 1 |
| Gihwala, D | 1 |
| Gonzalez, R | 1 |
| Herre, JM | 1 |
| Griffin, JC | 1 |
| Sauve, MJ | 1 |
| Sharkey, H | 1 |
| Thale, J | 1 |
| Gülker, H | 1 |
| Lichtlen, PR | 1 |
| Bertrix, L | 1 |
| Timour-Chah, Q | 1 |
| Lang, J | 1 |
| Lakhal, M | 1 |
| Faucon, G | 1 |
| Steinbeck, G | 1 |
| Bach, P | 1 |
| Haberl, R | 1 |
| Wehr, M | 1 |
| Cobbe, SM | 1 |
| Coskey, LA | 1 |
| Montgomery, DG | 1 |
| Feld, G | 1 |
| Hendrickson, J | 1 |
| Singh, PN | 1 |
| Khan, MI | 2 |
| Hamilton, JT | 2 |
| Manning, GW | 2 |
| Baum, T | 1 |
| Peters, JR | 1 |
| Eckfeld, DK | 1 |
| Varner, LL | 1 |
| Dinish, J | 1 |
| Metz, N | 1 |
| Shropshire, AT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT03819504] | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Change in the design of the study) | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT04612140] | 100 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| [NCT00000531] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| [NCT00000518] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol[NCT01572246] | 167 participants (Actual) | Observational | 2012-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
15 reviews available for sotalol and Ventricular Fibrillation
| Article | Year |
|---|---|
Effects of sotalol and d-sotalol on ventricular tachycardia and fibrillation induced by programmed electrical stimulation.
Topics: Adrenergic beta-Antagonists; Cardiac Pacing, Artificial; Clinical Trials as Topic; Heart Conduction | 1993 |
Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Defibrillators, Implantable; Humans; P | 1994 |
Class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra | 1994 |
Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Humans; Sotalol; Tachycardia, Ventricular; Ventricular | 1993 |
Evolving role of sotalol in the management of ventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Humans; Sotalol; Tachycardia, Ventricular; Ventricular Fibrillation | 1996 |
[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Combined Modality Therapy; Death, Sudd | 1996 |
Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Heart Arrest; Humans; Randomized Co | 1997 |
Sotalol: An important new antiarrhythmic.
Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibri | 1999 |
The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's.
Topics: Adrenergic beta-Antagonists; Defibrillators, Implantable; Electrophysiology; Female; Humans; Male; P | 2000 |
Are the antiarrhythmic-defibrillating effects of D-sotalol due to or despite the prolongation of the action potential duration?
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; | 1999 |
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 1999 |
Sotalol: the mechanism of its antiarrhythmic-defibrillating effect.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cytoprotection; Heart Conduction Syste | 2001 |
Antiarrhythmic drugs and ventricular defibrillation energy requirements.
Topics: Animals; Anti-Arrhythmia Agents; Defibrillators, Implantable; Humans; Phenethylamines; Sotalol; Sulf | 1999 |
How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Evaluation; Electric Stimulation; Electrocardiography, Ambu | 1992 |
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Topics: Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; | 1990 |
16 trials available for sotalol and Ventricular Fibrillation
| Article | Year |
|---|---|
The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2008 |
Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia.
Topics: Aged; Anti-Arrhythmia Agents; Female; Follow-Up Studies; Heart Arrest; Humans; Lidocaine; Male; Outp | 2005 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
[Implantable cardioverter defibrillator does not eliminate need for antiarrhythmic drugs in secondary prevention of life threatening ventricular arrhythmias. Results of OPTIC trial].
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Electric | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Electrocardiography, Amb | 1994 |
Antiarrhythmics Versus Implantable Defibrillators (AVID)--rationale, design, and methods.
Topics: Amiodarone; Cross-Over Studies; Defibrillators, Implantable; Humans; Prospective Studies; Quality of | 1995 |
Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Defibrillators, Implantable; Humans; P | 1994 |
Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial.
Topics: Actuarial Analysis; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambulat | 1993 |
Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias.
Topics: Cardiac Pacing, Artificial; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sotalol; Stereoiso | 1993 |
Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings.
Topics: Action Potentials; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug | 1996 |
[Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D-sotalol)].
Topics: Acute Disease; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Drug Therapy, Combination; Femal | 1996 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Defibrillators, Impl | 1999 |
A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cross-Over Studies; Hemodynamics; Humans; Middle | 2002 |
Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambulatory; Electrophysiolo | 1990 |
92 other studies available for sotalol and Ventricular Fibrillation
| Article | Year |
|---|---|
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
Topics: Action Potentials; Anti-Arrhythmia Agents; Atrial Function; Benzamides; Benzimidazoles; Biological A | 1992 |
Exercise-induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cardiopulmonary Resuscitation; Exe | 2021 |
Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Antazoline; Anti-Bacterial Agents; Arrhythm | 2018 |
Effects of combination of sotalol and verapamil on initiation, maintenance, and termination of ventricular fibrillation in swine hearts.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Cardiac Pacing, Artificial; Drug Syn | 2018 |
Verapamil reduces incidence of reentry during ventricular fibrillation in pigs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Heart Rate; Heart Ventricles; Sotalol; Swine; Ve | 2014 |
Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Drug-Related Side Effects and Adverse Reac | 2015 |
Combination antiarrhythmic therapy: 1 + 1 > 2?
Topics: Animals; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Heart Conduction Sy | 2008 |
d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationsh | 2009 |
Post induction arrhythmia in a renal patient: an unexpected risk factor.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Int | 2009 |
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2009 |
Empiric antiarrhythmic drug therapy in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: pragmatism or anachronism?
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dy | 2009 |
Atrial fibrillation degenerates into ventricular fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Defibrillators, Impla | 2010 |
A comparison of long-standing implantable cardioverter-defibrillator patients with and without appropriate therapy for ventricular arrhythmias: impact of a widening QRS.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Ther | 2011 |
First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Enzyme Inhibitors; Female; Infusions, Intravenous; In | 2011 |
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocar | 2012 |
Implantable cardiac defibrillators.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Humans; | 2002 |
Effect of sotalol and acute ventricular dilatation on action potential duration and dispersion of repolarization after defibrillation shocks.
Topics: Action Potentials; Animals; Catheterization; Electric Countershock; Heart; Heart Ventricles; Male; R | 2003 |
Electrical heterogeneity and arrhythmogenesis: importance of conduction velocity dispersion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, Animal; Ele | 2003 |
Effectiveness of sotalol treatment in symptomatic Brugada syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Genetic Predisp | 2004 |
Proarrhythmias and antiarrhythmias: two sides of the same coin.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2005 |
Potential proarrhythmic effect of biventricular pacing: fact or myth?
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2005 |
Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; California; Dose-Response R | 2006 |
Effects of procainamide and sotalol on restitution properties, dispersion of refractoriness, and ventricular fibrillation activation patterns in pigs.
Topics: Animals; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Heart Conduction Sy | 2008 |
Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiograp | 1984 |
Comparative antiarrhythmic activity of quinidine combined with propranolol and with sotalol.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Dogs; Drug Interactions; Female; Heart | 1981 |
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias.
Topics: Adrenergic beta-Antagonists; Atenolol; Electrocardiography; Heart Ventricles; Humans; Kinetics; Male | 1981 |
Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Dogs; Dose-Response Relation | 1984 |
Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; | 1984 |
Sotalol, prolonged Q-T interval, and ventricular tachyarrhythmias.
Topics: Adult; Electrocardiography; Humans; Male; Middle Aged; Sotalol; Ventricular Fibrillation | 1981 |
Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Dogs; Female; Halothane; Ligation; Male; Myocardial Reperfusion; Pe | 1995 |
AVID necessity.
Topics: Amiodarone; Arrhythmias, Cardiac; Bias; Clinical Trials as Topic; Defibrillators, Implantable; Ethic | 1994 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disea | 1995 |
Antifibrillatory effects of class III antiarrhythmic drugs: comparative study with flecainide.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Bretylium Compounds; Dogs; Electric Stimulati | 1993 |
Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Cells, Cultured; Dogs; Electric Stimulation; | 1995 |
Dispersion of ventricular refractoriness in experimental myocardial infarction: effect of sotalol.
Topics: Animals; Cardiac Pacing, Artificial; Dogs; Female; Male; Myocardial Infarction; Refractory Period, E | 1994 |
Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming.
Topics: Aged; Atrial Fibrillation; Defibrillators, Implantable; Electrocardiography; Electrophysiology; Equi | 1994 |
Beta-receptor blockade in preventing sudden death.
Topics: Adrenergic beta-Antagonists; Atenolol; Death, Sudden, Cardiac; Humans; Metoprolol; Practolol; Sotalo | 1993 |
Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
Topics: Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrophysiology; Female; Humans; Male; Middle | 1994 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
[Reproducible ventricular flutter during programming of a DDD pacemaker].
Topics: Female; Heart Block; Humans; Middle Aged; Pacemaker, Artificial; Sotalol; Ventricular Fibrillation | 1993 |
Effect of sotalol on ventricular fibrillation and defibrillation in humans.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Defibrillator | 1993 |
Sotalol for cardiac arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Sotalol; Tachycardia | 1993 |
Sotalol facilitates spontaneous ventricular defibrillation by enhancing intercellular coupling. An entirely new mechanism for its antiarrhythmic action.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Cell Communication; Cell Hypoxia; Culture Techniques; Elec | 1995 |
A simulation study used to design the sequential monitoring plan for a clinical trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Computer Simulation; Decision Making; Defibrillators, Implantabl | 1995 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Dogs; Electrocardiography; Heart Rate; Myocardial I | 1995 |
Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
Topics: Administration, Oral; Case-Control Studies; Combined Modality Therapy; Coronary Disease; Defibrillat | 1996 |
The vulnerable period for low and high energy T-wave shocks: role of dispersion of repolarisation and effect of d-sotalol.
Topics: Action Potentials; Animals; Electric Stimulation; Electrocardiography; Heart Conduction System; Male | 1996 |
From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduct | 1996 |
The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016.
Topics: Anesthesia, Inhalation; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Guine | 1996 |
Is cyclic AMP involved in the defibrillating effect of sotalol?
Topics: Amino Acid Sequence; Animals; Anti-Arrhythmia Agents; Cyclic AMP; Cyclic AMP-Dependent Protein Kinas | 1995 |
Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle | 1997 |
Clinical predictors of defibrillation energy requirements.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Coronary Disease; Defi | 1997 |
Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Electric Stimulation; Female; Follow-Up Studies; Heart | 1997 |
Tricyclic poisoning--successful management of ventricular fibrillation following massive overdose of imipramine.
Topics: Adrenergic Agonists; Adult; Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Critical Care; | 1997 |
Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,l-sotalol and flecainide in the isolated rabbit heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dilatation, Pathologic; Electrocardiography; Fle | 1998 |
Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias.
Topics: Anti-Arrhythmia Agents; Humans; Sotalol; Tachycardia, Ventricular; Ventricular Fibrillation | 1999 |
Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Rec | 1999 |
Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac | 1999 |
Alteration of ventricular fibrillation by flecainide, verapamil, and sotalol: an experimental study.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrophysiology; Flecainide; Heart Co | 2000 |
[Ion channels and arrhythmias].
Topics: Action Potentials; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrial Fib | 2000 |
Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Angiography; Death, Sudden, Cardi | 2000 |
Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Dogs; Dose-Response Relationship, Drug; Electrocardiogr | 2000 |
[Role of determination of QT dispersal intervals in anti-arrhythmia therapy].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Electrocar | 1999 |
Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
Topics: Animals; Anti-Arrhythmia Agents; Cats; Dose-Response Relationship, Drug; Electric Stimulation; Femal | 2001 |
Influence of the adrenal medulla on cardiac rhythm disturbances following acute coronary artery occlusions.
Topics: Adrenal Medulla; Animals; Arrhythmias, Cardiac; Cats; Coronary Disease; Epinephrine; Female; Lidocai | 1975 |
Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle.
Topics: Action Potentials; Administration, Oral; Aged; Amiodarone; Cardiac Pacing, Artificial; Female; Heart | 1992 |
Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Atrioventricular Node; Benzimidazoles; Dogs; Electrocar | 1992 |
Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.
Topics: Action Potentials; Anesthesia; Animals; Anti-Arrhythmia Agents; Dogs; Heart; Heart Ventricles; Hemod | 1992 |
Comparative antifibrillatory effects of d- and dl-sotalol in normal and ischaemic ventricular muscle of the cat.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cats; Coronary Disease; Female; Heart; | 1990 |
Life threatening 'epilepsy'.
Topics: Child, Preschool; Diagnosis, Differential; Epilepsy; Female; Humans; Sotalol; Tachycardia; Unconscio | 1991 |
Sotalol in patients with life-threatening ventricular tachyarrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Angiography; Coronary Disease; Electric Stimulation; E | 1990 |
DL and D sotalol decrease defibrillation energy requirements.
Topics: Animals; Dogs; Electric Countershock; Electrocardiography; Enflurane; Female; Fentanyl; Male; Pentob | 1989 |
Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats.
Topics: Animals; Arrhythmias, Cardiac; Electrophysiology; Hemodynamics; In Vitro Techniques; Male; Myocardia | 1989 |
Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Chronic Disease; Drug Evaluation; Ele | 1989 |
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Topics: Aged; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1989 |
Acute induction of sustained ventricular tachycardia: a new porcine model.
Topics: Animals; Disease Models, Animal; Electric Stimulation; Electrocardiography; Heart; Heart Ventricles; | 1989 |
Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP.
Topics: Acute Disease; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Blood Pressure; Coronary Circu | 1986 |
Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sotalol; Tachycardia; | 1988 |
Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; Female; Heart Conduct | 1987 |
[Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography | 1987 |
Inhibition of quinidine-propranolol elevation of the ventricular fibrillation threshold by bilateral stellectomy+vagotomy in the anesthetized dog.
Topics: Anesthesia; Animals; Denervation; Dogs; Electric Stimulation; Female; Heart; Male; Propranolol; Quin | 1986 |
Protection against ventricular and atrial fibrillation by sotalol.
Topics: Action Potentials; Animals; Atrial Fibrillation; Cardiopulmonary Bypass; Dogs; Heart; Sotalol; Ventr | 1986 |
Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Female; Heart Rate; | 1986 |
[QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
Topics: Adult; Aged; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Electrocardiography; Female; Heart | 1986 |
Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; | 1985 |
Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Death, Sudden; Diseas | 1985 |
Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Topics: Adult; Aged; Electrocardiography; Electrophysiology; Female; Heart Block; Humans; Injections, Intrav | 1985 |
Early arrhythmias following experimental coronary occlusion in conscious dogs and their modification by beta-adrenoceptor blocking drugs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Consciousn | 1973 |
Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Animals; Coronary Disease; Disease Models | 1972 |
Elevation of ventricular fibrillatory threshold by beta-adrenergic blocking agents.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Anti-Arrhythmia Agents; Blood Pressure; Dogs; Dose | 1972 |